Bath Savings Trust Co increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,439 shares of the biopharmaceutical company’s stock after buying an additional 2,033 shares during the period. Celgene Corp. accounts for approximately 2.9% of Bath Savings Trust Co’s investment portfolio, making the stock its 8th largest position. Bath Savings Trust Co’s holdings in Celgene Corp. were worth $9,140,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of CELG. Ngam Advisors L.P. raised its position in shares of Celgene Corp. by 3.6% in the second quarter. Ngam Advisors L.P. now owns 166,196 shares of the biopharmaceutical company’s stock worth $16,392,000 after buying an additional 5,707 shares during the period. Atwood & Palmer Inc. raised its position in shares of Celgene Corp. by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock worth $15,420,000 after buying an additional 2,543 shares during the period. Fisher Asset Management LLC raised its position in shares of Celgene Corp. by 3.0% in the second quarter. Fisher Asset Management LLC now owns 204,128 shares of the biopharmaceutical company’s stock worth $21,109,000 after buying an additional 5,968 shares during the period. First Republic Investment Management Inc. raised its position in shares of Celgene Corp. by 5.6% in the first quarter. First Republic Investment Management Inc. now owns 455,197 shares of the biopharmaceutical company’s stock worth $45,562,000 after buying an additional 24,245 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Celgene Corp. by 0.8% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,488,765 shares of the biopharmaceutical company’s stock worth $245,467,000 after buying an additional 20,006 shares during the period. Hedge funds and other institutional investors own 77.82% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.09% during trading on Friday, hitting $121.97. 5,048,365 shares of the stock were exchanged. The stock has a market cap of $94.55 billion, a PE ratio of 46.32 and a beta of 1.71. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $127.00. The firm has a 50 day moving average of $106.39 and a 200-day moving average of $105.91.

Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. Equities research analysts anticipate that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on CELG shares. Vetr lowered shares of Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $115.50 price target on the stock. in a report on Monday, October 31st. BTIG Research reissued a “buy” rating and set a $138.00 target price on shares of Celgene Corp. in a research note on Sunday, August 21st. BMO Capital Markets reissued an “outperform” rating and set a $141.00 target price on shares of Celgene Corp. in a research note on Monday, October 3rd. JPMorgan Chase & Co. reissued an “overweight” rating and set a $136.00 target price on shares of Celgene Corp. in a research note on Friday, August 19th. Finally, Jefferies Group reissued a “buy” rating and set a $134.00 target price on shares of Celgene Corp. in a research note on Monday, October 17th. Four equities research analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $135.74.

In other news, Director Gilla Kaplan sold 9,710 shares of Celgene Corp. stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the sale, the director now owns 72,142 shares in the company, valued at $7,678,794.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael D. Casey sold 43,134 shares of Celgene Corp. stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $114.01, for a total transaction of $4,917,707.34. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.